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Abstract Non-alcoholic fatty liver disease (NAFLD) is
reaching epidemic proportions in patients with type 2 diabe-
tes. Patients with NAFLD are at increased risk of more ag-
gressive liver disease (non-alcoholic steatohepatitis [NASH])
and at a higher risk of death from cirrhosis, hepatocellular
carcinoma and cardiovascular disease. Dysfunctional adipose
tissue and insulin resistance play an important role in the path-
ogenesis of NASH, creating the conditions for hepatocyte
lipotoxicity. Mitochondrial defects are at the core of the para-
digm linking chronic excess substrate supply, insulin resis-
tance and NASH. Recent work indicates that patients with
NASH have more severe insulin resistance and lipotoxicity
compared with matched obese controls with only isolated
steatosis. This review focuses on available agents and future
drugs under development for the treatment of NAFLD/NASH
in type 2 diabetes. Reversal of lipotoxicity with pioglitazone is
associated with significant histological improvement, which
occurs within 6 months and persists with continued treatment
(or for at least 3 years) in patients with prediabetes or type 2
diabetes, holding potential to modify the natural history of the
disease. These results also suggest that pioglitazone may be-
come the standard of care for this population. Benefit has also
been reported in non-diabetic patients. Recent promising re-
sults with glucagon-like peptide 1 receptor agonists have
opened another new treatment avenue for NASH. Many
agents in Phase 2-3 of development are being tested, aiming
to restore glucose/lipid metabolism, ameliorate adipose tissue
and liver inflammation, or to inhibit liver fibrosis. By targeting
a diversity of relevant pathways, combination therapy in
NASH will likely provide greater success in the future. In
summary, increased clinical awareness and improved screen-
ing strategies (as currently done for diabetic retinopathy and
nephropathy) are needed, to translate recent treatment prog-
ress into early treatment and improved quality of life for pa-
tients with type 2 diabetes and NASH. This review summa-
rises a presentation given at the symposium ‘The liver in fo-
cus’ at the 2015 annual meeting of the EASD. It is accompa-
nied by two other reviews on topics from this symposium (by
John Jones, DOI: 10.1007/s00125-016-3940-5, and by
Hannele Yki-Järvinen, DOI: 10.1007/s00125-016-3944-1)
and a commentary by the Session Chair, Michael Roden
(DOI: 10.1007/s00125-016-3911-x).
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Why treat NASH in patients with type 2 diabetes?
Non-alcoholic fatty liver disease (NAFLD) is a frequent comor-
bidity in both paediatric and adult populations, in particular in
the setting of obesity and type 2 diabetes [1–3]. It is estimated
that between 75 million to 100 million individuals in the USA
may have NAFLD [2], with high rates also reported worldwide
[1]. The magnitude of the epidemic will make screening imper-
ative, particularly in obese patients with type 2 diabetes, who
are at the highest risk of developing its more aggressive form
with hepatocyte injury (NASH). Patients with diabetes are also
at a higher risk of fibrosis, end-stage liver disease and hepato-
cellular carcinoma (HCC), as well as extra-hepatic complica-
tions [4]. However, few studies have systematically screened
patients with type 2 diabetes. In our experience, about 70% of
obese patients with diabetes have NAFLD and as many as
30–40% have NASH [5–7]. The prevalence of both remains
high even when plasma aminotransferase concentration is nor-
mal, with about half having steatosis (whenmeasured by proton
magnetic resonance imaging and spectroscopy [1H-MRS]),
about one-third having NASH and many early fibrosis [8].
Other investigators have reported similarly high rates of
steatosis (~70%) [9–12] and fibrosis (17–55%) [11–13]. The
results of two recent large screening studies (one from Hong
Kong [n=1,918] [13] and another from Rotterdam [n=3,041]
[14]) were consistent with this, reporting that fibrosis affects
one out of every six middle-aged patients with diabetes. Of
note, on histology, isolated steatosis (i.e. without features of
hepatocyte necrosis or inflammation) is no longer considered
a ‘benign’ condition, at least in type 2 diabetes, as emerging
evidence indicates that many patients with isolated steatosis
develop hepatocyte injury and fibrosis over time [15]. Liver
fibrosis is the single best predictor of future cirrhosis [16, 17]
and it occurs much more frequently in diabetes [18].
It should also be noted that NAFLD is becoming a major
cause of HCC in the USA. A recent study reported that between
2004 and 2009, HCC related to NASH increased by 9% annu-
ally and was associated with shorter survival time compared
with other predisposing aetiologies [19]. Lack of systematic
screening and treatment for NASH, even among hepatologists
[20], has led to it being massively underdiagnosed, which ex-
plains why NASH is the second largest cause of cirrhosis and
liver transplantation in the USA [21].
Another major reason for addressing NAFLD in diabetes is
its strong association with cardiovascular disease (CVD) [1, 2,
22].While most physicians place a high priority on preventing
macrovascular complications in type 2 diabetes, few are aware
that the presence of NAFLD appears to significantly increase
the risk. Although the nature of this association remains a
subject of intense investigation, there is good evidence that
NAFLD promotes dyslipidaemia [23], hyperinsulinaemia
[24] and subclinical inflammation [1, 2, 22], all of which are
potentially atherogenic risk factors. The presence of NAFLD
may also worsen microvascular disease and other comorbidi-
ties often present in diabetes [1, 4].
In summary, patients with type 2 diabetes who also have
NASH appear to be at a significantly higher risk of death from
either cirrhosis, HCC and/or CVD. A specific screening strat-
egy for this population must be developed and implemented,
as has been done for diabetic microvascular complications [1,
25], and included in future guidelines [26, 27].
Available pharmacological agents for the treatment
of NASH in patients with type 2 diabetes
Insulin-sensitisers in NASH Restoring insulin action is a
major treatment target given the central role of adipose tissue
insulin resistance and ‘lipotoxicity’ in the pathogenesis of
NASH [1]. Insulin sensitivity and hepatic steatosis usually
improve with lifestyle intervention in proportion to the mag-
nitude of weight loss. Significant reversal of hepatocyte injury
requires weight loss of about 10% [1, 2, 28]. Bariatric surgery
also improves NASH [28]. In contrast, long-term improve-
ment of fibrosis by either lifestyle intervention or bariatric
surgery is uncertain owing to a lack of controlled prospective
studies beyond 12 months’ duration (reviewed in [26, 28]).
Insulin-sensitisers have been widely tested in NAFLD.
Early open-label studies with metformin suggested a histolog-
ical benefit [29, 30]. However, a specific effect of the
biguanide was difficult to establish given the larger than ex-
pected associated weight loss in these studies, while more
recent randomised controlled trials (RCTs) have yielded neg-
ative results in both children [31] and adults (reviewed in [1, 3,
26, 28]). While the aetiology of NASH is multifactorial, un-
abated lipolysis in dysfunctional/insulin-resistant adipose
plays a key role by promoting ectopic triacylglycerol accumu-
lation in many tissues [1–3]. Adipose tissue dysfunction and
hepatic insulin resistance are more severe in diabetic patients
with NASH compared with matched obese controls with only
isolated steatosis [32], and mitochondrial defects appear to be
at the core of the paradigm linking excess substrate supply,
insulin resistance, lipotoxicity and NASH [33]. Recent studies
from our laboratory [34, 35], and others [36–38], support this
view. In animal models of diet-induced NASH (C57BL/6
mice fed a high-trans-fat, high-fructose diet for 24 weeks)
hepatic mitochondrial fluxes are increased, but not enough
to prevent the formation of inflammatory cytokines, lipid per-
oxidation products and other toxic lipid metabolites
(ceramides, diacylglycerols and acylcarnitines, among
others), suggesting inadequate adaptation with inefficient
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disposal of excess fatty acids through the tricarboxylic acid
(TCA) cycle [34]. Recent human studies indicate inadequate
mitochondrial adaptation despite increased TCA cycle activity
in obese patients with hepatic steatosis [39]. In patients with
NASH, mitochondrial mass is greater but is characterised by
proton leakage, reduced antioxidant capacity and more prone
to trigger inflammation [38]. In these provocative studies only
a handful of patients were studied, so much more remains to be
learned in relation to factors such as ethnicity, presence or
absence of diabetes, ageing, genetic polymorphisms (e.g.
PNLPA3, TM6SF2) and response to weight loss or pharmaco-
therapy. It has been established that mitochondrial oxidative
capacity must retain its ability to be highly adaptable (retain
‘metabolic flexibility’) to changing metabolic demands in order
to prevent cell injury and activation of apoptotic pathways.
Under conditions of chronic overfeeding, as observed in obesity
or type 2 diabetes, metabolic flexibility is lost. This hypothesis
clearly requires further experimental validation. However, recent
proof-of-concept experimental approaches that relieve mito-
chondrial demand either by weight loss or hormonal manipula-
tion [40], or more specifically, by mild mitochondrial
uncoupling using the protonophore 2,4-dinitrophenol (DNP)
[36], reverse hepatic triacylglycerol accumulation and NASH.
Within this context, thiazolidinediones (TZDs) are ligands
that target the transcription factor peroxisome proliferator-
activated receptor (PPAR)-γ, with broad effects on glucose/
lipid metabolism through modulation of substrate supply, in-
sulin signalling and mitochondrial fatty acid oxidation [1, 41].
In humans with NASH, pioglitazone enhances insulin sensi-
tivity and prevents excessive rates of lipolysis [42–44]. The
positive effects of PPAR-γ action on adipocyte biology trans-
late into a two- to threefold increase in plasma adiponectin
concentration [44]. In recent work, Bril et al [45] reported that
the response to pioglitazone in NASH can be predicted by the
increase in plasma adiponectin levels within the first 1–3
months after treatment initiation. It has been about a decade
since Belfort et al [42] first reported in a proof-of-concept
study that in patients with NASH and either impaired glucose
tolerance or type 2 diabetes, pioglitazone treatment signifi-
cantly ameliorated hepatic steatosis and necroinflammation.
The NAS improved for most participants, while treatment
difference in resolution of NASH vs placebo occured in about
one-third. Pioglitazone also reduced liver fibrosis compared
with baseline (p=0.002), but not when compared with place-
bo (p=0.08). This RCT was important in establishing that
NASH could be reversed within a relatively short period of
time (6 months). Pioglitazone also prevents the progression
from impaired glucose tolerance to diabetes [46], and one may
speculate that this effect is tied to its ability to reverse
NAFLD/NASH [47]. Histological improvement with pioglit-
azone in NASH was later also reported in patients without
diabetes [48, 49]. Recently, a 3 year study in 101 patients with
NASH and either impaired fasting glucose and/or impaired
glucose tolerance or type 2 diabetes confirmed its long-term
safety and efficacy in this population (K. Cusi, B. Orsak, F.
Bril, R. Lomonaco, J. Hecht, C. Ortiz-Lopez, unpublished
results). Taken together, these results suggest that pioglitazone
may modify the natural history of the disease. No patient
discontinued the trial due to a pioglitazone-induced adverse
event and weight gain was modest overall (3 kg over 3 years).
Weight gain with pioglitazone treatment is primarily due to
improved insulin action and enhanced adipocyte triacylglyc-
erol storage, and less often the result of fluid retention [50, 51].
Pioglitazone decreases cardiovascular events [1, 41], a feature
frequently forgotten but of value in this population. However,
development of shortness of breath or congestive heart failure,
while rare, may occur in patients with type 2 diabetes and
NAFLD with undiagnosed diastolic dysfunction [52]. Bone
loss may occur with TZD treatment in women, and pioglita-
zone should not be used in pregnancy or in children or ado-
lescents [53]. A 10 year prospective study showed no associ-
ation between pioglitazone and bladder cancer [54].
Glucagon-like peptide 1 receptor agonists and dipeptidyl
peptidase 4 inhibitors Indirect evidence from animal studies
(reviewed in [1, 55]), and recent meta-analysis of clinical trials
of liraglutide in type 2 diabetes [56], have suggested that
glucagon-like peptide 1 receptor agonists (GLP-1RAs) could
improve NASH. However, clear evidence was lacking until
the landmark proof-of-concept study by Armstrong et al [57].
The investigators treated 52 obese insulin-resistant patients,
one-third of whom had type 2 diabetes, with liraglutide or
placebo for 48 weeks. Resolution of NASH was observed in
39% of liraglutide-treated patients compared with 9% of pa-
tients in the placebo group (RR 4.3, 95% CI 1.0, 17.7;
p=0°019), a treatment difference of ~30%. In addition, there
was less progression of liver fibrosis over time in the treatment
group (p<0.05). Liver and adipose tissue insulin sensitivity
improved in a subset of patients that underwent careful glu-
cose turnover studies [58]. These results have created signifi-
cant excitement for additional GLP-1RA studies in NASH to
understand the relative contribution of unspecific mechanisms
such as changes in weight, insulin sensitivity or glucotoxicity
[59] vs effects on specific hepatocyte GLP-1 signalling path-
ways [60, 61].
In contrast, studies with dipeptidyl peptidase 4 (DPP-4)
inhibitors have reported mixed results. Sitagliptin has been
reported to be neutral [62] or to decrease [63] plasma amino-
transferases, although their overall impact on liver histology is
unknown. In diabetic patients with mild steatosis, Macauley
et al [64] observed a small but significant reduction (from
7.3% to 5.3%, normal ≤5.5%; p=0.001) in hepatic triacyl-
glycerol accumulation with vildagliptin treatment for
6 months, a change that correlated closely with the decrease
in fasting plasma concentration. Thus, hyperglycaemia may
be an important factor that promotes hepatic steatosis, as
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suggested in cross-sectional studies [8, 32], although the role
of reversing glucotoxicity per se on NASH (independent of
treating insulin resistance) has never been examined in an
RCT in type 2 diabetes.
Sodium–glucose cotransporter 2 (SGLT2) inhibitors
Control of hyperglycaemia by inhibition of proximal tubule
glucose reabsorption [65] is actively being investigated as a
potential approach for NAFLD in patients with type 2 diabe-
tes. A reduction in intrahepatic triacylglycerol accumulation
would be expected from a decrease in substrate supply to the
liver by the combined effects of normoglycaemia plus modest
weight loss and enhanced insulin sensitivity. In animal models
of NASH, sodium–glucose cotransporter 2 (SGLT2) inhibi-
tors have unique antifibrotic properties [66]. In patients with
diabetes, levels of plasma aminotransferases decrease during
treatment with SGLT2 [67, 68]. Recently, pooled data from
four 26 week placebo-controlled studies of canagliflozin
(n= 2313) and two 52 week active-controlled studies of
canagliflozin vs sitagliptin (n=1488) found significant reduc-
tions in plasma alanine aminotransferase (ALT) with
canagliflozin 300 mg compared with placebo or sitagliptin
[69]. Changes in aspartate aminotransferase (AST)/ALTwere
fully explained by the reduction in HbA1c and body weight.
Future studies are needed to define the role of SGLT2 inhib-
itors in the management of patients with NAFLD and type 2
diabetes.
Other therapeutic agents tested for the treatment of NASH
Many agents have been tested for the treatment of NASH
[1–3, 28, 55] but few have included a significant number of
patients with type 2 diabetes. Most have not improved liver
histology. Lipid-lowering agents have been tested extensively
and can be used safely in this population [26, 27], but statins
[70], ezetimibe [71], fibrates [72], niacin [72], omega-3 poly-
unsaturated fatty acids (PUFAs) [73] and colesevelam [74] do
not improve steatosis to a clinically meaningful extent (or
hepatocyte injury when examined; reviewed in [28, 55]).
Instead, amelioration of hepatocyte injury has been reported
with vitamin E in adults without type 2 diabetes at doses of
800 IU/day [49]. However, resolution of NASH was of bor-
derline significance (36% vs 21%, p=0.05 vs placebo) in
contrast to the effect of pioglitazone in the same trial (47%
vs 21%, p=0.001 vs placebo) [49]. In a controlled trial in non-
diabetic children with NASH, treatment with vitamin E or
metformin had overall negative effects [31]. Vitamin E may
decrease intracellular oxidative stress, although the mecha-
nism of action is unclear. The long-term safety of vitamin E
in patients with NASH remains to be established given its
controversial increase in the risk of prostate cancer with
long-term exposure [75]. An ongoing RCTwill soon establish
its role in patients with type 2 diabetes, either alone or
combined with pioglitazone (NCT01002547). Finally,
pentoxifylline, a TNF-α agonist and non-selective phospho-
diesterase inhibitor, has been studied in NASH in two small
controlled 12 month studies. Van Wagner et al [76] reported
no histological improvement in 30 patients, while another
small trial (n=26) observed a modest benefit on steatosis,
lobular inflammation and fibrosis [77]. Larger studies are
clearly needed to establish its role in NASH.
Future treatments for patients with NASH
From the previous sections it is evident that additional agents
are needed for the treatment of NASH. Moreover, no existing
agent tested has been specifically approved to this end. This
has led to an explosion of agents currently under investigation.
Importantly, most studies now include a large number of pa-
tients with type 2 diabetes given their higher risk of disease
progression.
Many approaches have been tested. Table 1 includes agents
at more advanced stages of development (Phase 2a/2b or early
Phase 3 trials). But the challenge ahead is substantial. For ex-
ample, attempts to control triacylglycerol synthesis, such as
with 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)
[78] or stearoyl coenzyme A desaturase (SCD)-1 pathways
[79] have led to overall discouraging results. Greater success
has been achieved by targeting PPARα/PPARδ with the dual
agonist elafibranor (GFT505) [80], a partial PPARα agonist
with about 60% of the maximal response (Emax) of fenofibrate
[81]. Dual PPARα and PPARδ activation mitigates inflamma-
tion and improves hepatic insulin sensitivity in vivo [82] and in
insulin-resistant patients [83]. In contrast, the PPARα agonist
fenofibrate has not been associated with a decrease in insulin
resistance or plasma aminotransferase concentration in patients
with themetabolic syndrome [84] or decreased hepatic steatosis
in patients with NAFLD [72]. Despite the above strong ratio-
nale, discouraging results were reported after 52 weeks of
elafibranor treatment in 276 patients with biopsy-proven
NASH (~40% with type 2 diabetes) as it failed to meet the
primary outcome of resolution of NASH without worsening
of fibrosis [84]. This was, at least in part, due to many patients
having borderline NASH on liver histology before treatment.
However, resolution of NASH (20% vs 11%, p=0.018) and
improved scores of hepatocyte injury and fibrosis were noted at
the higher dose (120 mg/day) in patients with more severe
disease at baseline (NAFLD activity score [NAS] ≥4; n=234)
[85]. These results have been the basis for an ongoing large
multicentre RCT with elafibranor enrolling only patients with
more advanced liver disease (NAS≥4) (NCT02704403) [85].
A different strategy involves more directly targeting in-
flammation by inhibition of C-C chemokine receptors type 2
(CCR2) and type 5 (CCR5), which mediate monocyte and
macrophage infiltration and inflammation in adipose tissue
[86, 87]. Overexpression of CCR2 and CCR5 receptors and
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their ligands in adipose tissue of obese patients is associated
with increased inflammation and insulin resistance.
Cenicriviroc is a potent inhibitor of ligand binding of CCR2
and CCR5 with antifibrotic properties in animal models of
liver/kidney fibrosis. Post hoc analysis of Phase 2b studies
in HIV-1 patients revealed that cenicriviroc treatment im-
proved plasma biomarkers of fibrosis (AST to Platelet Ratio
Index [APRI] and Fibrosis 4 calculator [FIB-4] scores). Its
mechanism of action in humans is being actively studied in
obese, insulin-resistant individuals at risk of NAFLD (ORION
study; NCT02330549), and in a large controlled multicentre
trial in patients with NASH who are at increased risk of dis-
ease progression due to the presence of ≥1 risk factor such as
the metabolic syndrome, type 2 diabetes or hepatic fibrosis
(CENTAUR; NCT02217475) [88].
Given that fibrosis is the primary determinant of long-term
adverse outcomes [16, 17], several novel agents are specifically
targeting fibrosis-related pathways. Approaches include inhibi-
tion of apoptotic pathways with the pan-caspase inhibitor
emricasan, a compound that has been recently granted fast
track designation by the United States Food and Drug
Administration and is being tested in a Phase 2b clinical trial
in NASH cirrhosis (EmricasaN, a Caspase inhibitOR, for
Evaluation [ENCORE-NF]). Another strategy is treatment of
advanced fibrosis targeting galectins, a family of proteins with
high affinity to galactose-containing glycoproteins present on
cell surfaces and the extracellular matrix [89]. Galectin-3 pro-
tein is highly expressed in immune cells and has been associated
with inflammation and fibrosis in several disease models, in-
cluding hepatic fibrosis. A Phase 2a multicentre trial is under-
way in individuals with portal hypertension and NASH cir-
rhosis (NCT02462967). Other approaches in Phase 2 studies
aimed at controlling fibrogenesis include targeting growth and
inflammation through the fibroblast growth factor 21 (FGF21)
pathway [90] (compound BMS986036, NCT02413372), or
preventing collagen cross-linking by inhibiting lysyl
oxidase-like 2 (LOXL2) enzyme activity with the monoclonal
antibody simtuzumab (being tested in NASH patients with
[NCT01672879] or without [NCT01672866] cirrhosis).
Finally, histological improvement may be achieved in
NASH by modulation of hepatic glucose and lipid metabolism
through farnesoid X receptor (FXR) pathways [91], as recently
shown with the bile acid derivative 6-ethylchenodeoxycholic
acid (obeticholic acid) [92]. The primary outcome of a decrease
in the NAS by ≥2 without worsening of fibrosis was reached in
45% of patients treated with obeticholic acid vs 21% on placebo
(RR 1.9, 95% CI 1.3, 2.8; p=0.0002; treatment effect ~24%).
However, to reach this prespecified primary endpoint, change in
the NAS did not have to necessarily include ballooning or two
separate NAS variables. This departure from prior trials by the
NASH Clinical Research Network [31, 49], in part aimed at
simplifying the primary outcome, has made comparisons with
other RCTs difficult [31, 49, 84].While resolution of NASH did
not change significantly (22% vs 13% on placebo, p=0.08),
individual histological outcomes improved compared with pla-
cebo: steatosis 61% vs 38% (p=0.001), inflammation 53% vs
35% (p=0.006), ballooning 46% vs 31% (p=0.03) and fibrosis
35% vs 19% (p=0.004), giving a treatment difference vs pla-
cebo of between ~15% and 23%. There has been some concern
about the increase from baseline in plasma LDL-cholesterol and
the reduction in HDL-cholesterol levels, as well as the observed
worsening of insulin sensitivity (according to HOMA-IR). Of
note, changes in fasting plasma insulin during the trial were
confounded, at least in part, by patients with diabetes on exog-
enous insulin during the study. However, a modest improve-
ment in hepatic insulin sensitivity is observed with short-term
Table 1 Pharmaceutical agents under development for the treatment of NASH
Therapeutic agent Manufacturer Target Proposed mode of action
BMS986036 Bristol-Myers Squibb Modulation of FGF21 metabolism Improvement of hepatic lipid and glucose
metabolism; anti-inflammatory
Cenicriviroc Tobira Therapeutics CCR2 and CCR5 Inhibition of CCR2- and CCR5-mediated
monocyte/macrophage infiltration and inflammation
Elafibranor Genfit Modulation of hepatic PPARα
and PPARδ pathways
Stimulation of NEFA oxidation; improvement of
lipid and glucose metabolism; prevention
of inflammation
Emricasan Conatus Pharmaceuticals Caspase pathways (pan-caspase inhibitor) Inhibition of fibrosis by blocking caspase
protease activation and apoptosis pathways
GR-MD-02 Galectin Therapeutics Galectin-3 inhibitor Prevention of inflammation and fibrosis
Obeticholic acid Intercept Pharmaceuticals FXR agonist Regulation of hepatic glucose and lipid metabolism
Px-104 Phenex Pharmaceuticals/
Gilead Sciences
FXR agonist Regulation of hepatic glucose and lipid metabolism
Simtuzumab Gilead Sciences LOXL2 enzyme activity Inhibition of fibrosis by a LOXL2 monoclonal antibody
Agents are listed in alphabetical order
FXR, Farnesoid X receptor; LOXL2, Lysyl oxidase-like 2
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use of obeticholic acid [93] at the daily dose of 25 mg used in
the Farnesoid X Receptor Ligand Obeticholic Acid in NASH
Treatment (FLINT) [92]. A larger multicentre study is under-
way to fully assess its long-term efficacy and safety.
Conclusions: perspective for the future
Today there is amuch greater awareness of the severemetabolic
and liver-specific complications associated with NASH.Within
this context, there is growing consensus to replace the acronym
‘NASH’, a disease of ‘not being alcoholic steatohepatitis’ with
a more descriptive name that would help clinicians conceptual-
ly grasp the condition to be diagnosed and treated [1, 94, 95].
As reviewed earlier, there are many intracellular pathways that
contribute to hepatocyte injury, and the heterogeneous nature of
the disease makes a unifying name difficult. However, this
problem is also true for most chronic diseases, including type
2 diabetes. A name that highlights the central role of hepatocyte
lipotoxicity secondary to adipose tissue insulin resistance char-
acteristic of obesity would be fitting. Lipotoxicity primes cells
to mitochondrial dysfunction and makes them more vulnerable
to toxic lipid metabolites, oxidative stress and activation of
multiple inflammatory pathways [1, 94]. Future work needs
to deepen our understanding of the crosstalk between liver
and adipose tissue, but the name ‘lipotoxic liver disease’would
encompass a significant aspect of the disease and serve as a
reminder to clinicians about the important role of dysregulated
adipose tissue in NAFLD.
Specific screening and treatment recommendations for pa-
tients with type 2 diabetes and NASH will need to be developed
and actively pursued in the clinic. Screening for NASH in type 2
diabetes, particularly in obese patients, should be encouraged as
is currently done for microvascular complications of diabetes
such as retinopathy, neuropathy and nephropathy. Only early
intervention is likely to modify the natural history of the disease
and halt the growing epidemic of NASH [21]. Recent studies
support such an approach, as one in six middle-aged patients
with type 2 diabetes have liver fibrosis [13, 14, 25]. There is
recent evidence of a long-term safe and effective treatment for
this population in pioglitazone (K. Cusi et al, unpublished re-
sults), which will become to NASH what metformin is to type
2 diabetes today—first-line therapy and the background agent for
combination strategies. This should not undermine the search for
other pharmacological agents targeting the many dysfunctional
pathways in NASH discussed above. Of note, drug development
should target resolution ofNASH, not isolated steatosis, although
in early exploratory studies significant reduction in liver triacyl-
glycerol content on imaging (1H-MRS) may potentially predict
improvement in NASH. The magnitude of improvement on 1H-
MRS imaging that translates into resolution of NASH is un-
known at the present time, but is likely to depend on the mech-
anism of action of a specific compound. As new agents become
available, it is likely that combination therapy will become wide-
ly accepted for such a heterogeneous disease such asNASH, as is
common practice for the treatment of type 2 diabetes or
hypertension.
Future studies should explore the role of glycaemic control
per se in NASH, as has been investigated for microvascular
complications of diabetes. No trial to date has addressed this
issue. There is also a need for long-term RCTs on the optimal
lifestyle intervention, how to improve adherence and on the best
macronutrient composition for NASH in type 2 diabetes. The
additional role of weight loss agents and of bariatric surgery
need to be better defined prospectively in controlled studies.
Drug development trials will need more consistency in their
trial design and primary outcomes, as well as improved research
networks for efficient recruitment into large multicentre RCTs.
Better standardisation across imaging methodologies and bio-
markers, with better correlation/validation with histology, will
be also imperative for the screening of large cohorts and the
assessment of treatment response.
In summary, while the diagnosis of NAFLD/NASH today
remains a challenge, screening with a combination of validat-
ed novel genetic, imaging and plasma biomarkers will in the
near future facilitate management. We are at an exciting time
where new awareness about the impact of NASH will prompt
earlier diagnosis and treatments that for the first timemay alter
the natural history of the disease and improve the quality of
life of millions of patients.
Funding Work by the author is supported by a VA Merit Award (1 I01
CX000167-01).
Duality of interest Kenneth Cusi (KC) has received research grant
support from Janssen Pharmaceutical Co. of Johnson & Johnson and
Novartis Pharmaceuticals, and is a consultant for Janssen
Pharmaceutical Co. of Johnson & Johnson, Eli Lilly and Company, and
Tobira Therapeutics, Inc.
Contribution statement The author was the sole contributor to this
paper.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Cusi K (2012) Role of obesity and lipotoxicity in the development
of nonalcoholic steatohepatitis: pathophysiology and clinical impli-
cations. Gastroenterology 142:711–725
2. Rinella ME (2015) Nonalcoholic fatty liver disease: a systematic
review. JAMA 313:2263–2273
Diabetologia (2016) 59:1112–1120 1117
3. Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease
review: diagnosis, treatment and outcomes. Clin Gastroenterol
Hepatol 13:2062-2070
4. Armstrong MJ, Adams LA, Canbay A, Syn W-K (2014)
Extrahepatic complications of nonalcoholic fatty liver disease.
Hepatology 59:1174–1197
5. Lomonaco R, Ortiz-Lopez C, Orsak B et al (2011) Role of ethnicity
in overweight and obese patients with nonalcoholic steatohepatitis.
Hepatology 54:837–845
6. MaximosM, Bril F, Portillo-Sanchez P et al (2015) The role of liver
fat and insulin resistance as determinants of plasma aminotransfer-
ase elevation in nonalcoholic fatty liver disease. Hepatology 61:
153–160
7. Bril F, Ortiz-Lopez C, Lomonaco R et al (2015) Clinical value of
liver ultrasound for the diagnosis of nonalcoholic fatty liver disease
in overweight and obese patients. Liver Int 35:2139–2146
8. Portillo-Sanchez P, Bril F, MaximosM et al (2015) High prevalence
of nonalcoholic fatty liver disease in patients with type 2 diabetes
mellitus and normal plasma aminotransferase levels. J Clin
Endocrinol Metab 100:2231–2238
9. Targher G, Bertolini L, Padovani R et al (2007) Prevalence of non-
alcoholic fatty liver disease and its association with cardiovascular
disease among type 2 diabetic patients. Diabetes Care 30:1212–
1218
10. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR
(2009) Prevalence and associated factors of non-alcoholic fatty liver
disease in patients with type-2 diabetes mellitus. Liver Int 29:113–
119
11. Leite NC, Villela-Nogueira CA, Pannain VL et al (2011)
Histopathological stages of nonalcoholic fatty liver disease in type
2 diabetes: prevalences and correlated factors. Liver Int 31:700–
706
12. Casey SP, Kemp WW, McLean CA, Topliss DJ, Adams LA,
Roberts SK (2012) A prospective evaluation of the role of transient
elastography for the detection of hepatic fibrosis in type 2 diabetes
without overt liver disease. Scand J Gastroenterol 47:836–841
13. Kwok R, Choi KC, Wong GL et al (2015) Screening diabetic pa-
tients for nonalcoholic fatty liver disease with controlled attenuation
parameter and liver stiffness measurements: a prospective cohort
study. Gut. doi:10.1136/gutjnl-2015-309265
14. Koehler EM, Plompen EP, Schouten JN, Hansen BE, Darwish
Murad S, Taimr P et al (2016) Presence of diabetes mellitus and
steatosis is associated with liver stiffness in a general population:
the Rotterdam study. Hepatology 63:138–147
15. Pais R, Charlotte F, Fedchuk L et al (2013) A systematic review of
follow-up biopsies reveals disease progression in patients with non-
alcoholic fatty liver. J Hepatol 59:550–556
16. Ekstedt M, Hagstrom H, Nasr P et al (2015) Fibrosis stage is the
strongest predictor for disease-specific mortality in NAFLD after up
to 33 years of follow-up. Hepatology 61:1547–1554
17. Angulo P, Kleiner DE, Dam-Larsen S et al (2015) Liver fibrosis, but
no other histologic features, is associated with long-term outcomes
of patients with nonalcoholic fatty liver disease. Gastroenterology
149:389.e310–397.e310
18. Raff EJ, Kakati D, Bloomer JR, Shoreibah M, Rasheed K, Singal
AK (2015) Diabetes mellitus predicts occurrence of cirrhosis an
hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver
diseases. J Clin Transl Hepatol 3:9–16
19. Younossi Z, Otgonsuren M, Henry L et al (2015) Association of
nonalcoholic fatty liver disease (NAFLD) with hepatocellular car-
cinoma (HCC) in the United States from 2004 to 2009. Hepatology
62:1723–1730
20. Rinella ME, Lominadze Z, Loomba R et al (2016) Practice patterns
in NAFLD and NASH: real life differs from published guidelines.
Ther Adv Gastroenterol 9:4–12
21. Wong RJ, Aguilar M, Cheung R et al (2015) Nonalcoholic
steatohepatitis is the second leading etiology of liver diseaseamong
adults awaiting liver transplantation in the United States.
Gastroenterology 48:547–555
22. Lonardo A, Sookoian S, Pirola CJ, Targher G (2015) Non-alcoholic
fatty liver disease and risk of cardiovascular disease. Metabolism.
doi:10.1016/j.metabol.2015.09.017
23. Bril F, Sninsky JJ, Baca AM et al (2016) Hepatic steatosis and
insulin resistance, but not steatohepatitis, promote atherogenic dys-
lipidemia in NAFLD. J Clin Endocrinol Metab 101:644–652
24. Bril F, Lomonaco R, Orsak B et al (2015) Relationship between
disease severity, hyperinsulinemia, and impaired insulin clearance
in patients with nonalcoholic steatohepatitis. Hepatology 59:2178–
2187
25. Ahmed A, Perumpail RB, Harrison SA (2016) High prevalence of
hepatic fibrosis in the setting of coexisting diabetes and hepatic
steatosis: a case for selective screening in the general population?
Hepatology 63:20–22
26. Chalasani N, Younossi Z, Lavine JE et al (2012) The diagnosis
and management of non-alcoholic fatty liver disease: practice
guideline by the American Association for the Study of Liver
Diseases, American College of Gastroenterology, and the
American Gastroenterological Association. Gastroenterology
142:1592–1609
27. European Association for the Study of the Liver (EASL), European
Association for the Study of Diabetes (EASD) and European
Association for the Study of Obesity (EASO) (2016) EASL–
EASD–EASO Clinical Practice Guidelines for the management of
non-alcoholic fatty liver disease. Diabetologia. doi:10.1007/
s00125-016-3902-y
28. Lomonaco R, Sunny NE, Bril F, Cusi K (2013) Nonalcoholic fatty
liver disease: current issues and novel treatment approaches. Drugs
73:1–14
29. Bugianesi E, Gentilcore E, Manini R et al (2005) A randomized
controlled trial of metformin versus vitamin E or prescriptive diet in
nonalcoholic fatty liver disease. Am J Gastroenterol 100:1082–
1090
30. LoombaR, Lutchman G, Kleiner DE et al (2009) Clinical trial: pilot
study of metformin for the treatment of non-alcoholic
steatohepatitis. Aliment Pharmacol Ther 29:172–182
31. Lavine JE, Schwimmer JB, Van Natta ML et al (2011) Effect of
vitamin E or metformin for treatment of nonalcoholic fatty liver
disease in children and adolescents: the TONIC randomized con-
trolled trial. JAMA 305:1659–1668
32. Lomonaco R, Bril F, Portillo-Sanchez P et al (2016) Metabolic
impact of nonalcoholic steatohepatitis (NASH) in obese pa-
tients with type 2 diabetes mellitus. Diabetes Care. doi:10.
2337/dc15-1876
33. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B (2013)
Mitochondrial adaptations and dysfunctions in nonalcoholic fatty
liver disease. Hepatology 58:1497–1507
34. Sunny NE, Kalavalapalli S, Bril F et al (2015) Cross-talk between
branched-chain amino acids and hepatic mitochondria is compro-
mised in nonalcoholic fatty liver disease. Am J Physiol Endocrinol
Metab 309:E311–E319
35. Patterson RE, Kalavalapalli S, Williams CM et al (2016)
Lipotoxicity in steatohepatitis occurs despite an increase in tricar-
boxylic acid cycle activity. Am J Physiol Endocrinol Metab. doi:
10.1152/ajpendo.00492.2015
36. Perry RJ, Zhang D, Zhang XM, Boyer JL, Shulman GI (2015)
Controlled-release mitochondrial protonophore reverses diabetes
and steatohepatitis in rats. Science 347:1253–1256
37. Satapati S, Kucejova B, Duarte JA et al (2015) Mitochondrial me-
tabolism mediates oxidative stress and inflammation in fatty liver. J
Clin Invest 125:4447–4462
1118 Diabetologia (2016) 59:1112–1120
38. Koliaki C, Szendroedi J, Jelenik T et al (2015) Adaptation of he-
patic mitochondrial function in humans with non-alcoholic fatty
liver or steatohepatitis. Cell Metab 21:739–746
39. Sunny NE, Parks EJ, Browning JD, Burgess SC (2011) Excessive
hepatic mitochondrial TCA cycle and gluconeogenesis in humans
with nonalcoholic fatty liver disease. Cell Metab 14:804–810
40. Finan B, Yang B, Ottaway N et al (2015) A rationally designed
monomeric peptide triagonist corrects obesity and diabetes in ro-
dents. Nat Med 21:27–36
41. Soccio RE, Chen ER, Lazar MA (2014) Thiazolidinediones and the
promise of insulin sensitization in type 2 diabetes. Cell Metab 20:
573–591
42. Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled
trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N
Engl J Med 355:2297–2307
43. Gastaldelli A, Harrison S, Belfort R et al (2009) Importance of
changes in adipose tissue insulin resistance to histological response
during thiazolidinedione treatment of patients with nonalcoholic
steatohepatitis. Hepatology 50:1087–1093
44. Gastaldelli A, Harrison S, Belfort-Aguiar R et al (2010)
Pioglitazone in the treatment of NASH: the role of adiponectin.
Aliment Pharmacol Ther 32:769–775
45. Bril F, Portillo Sanchez P, Maximos M et al (2015) Metabolic pre-
dictors of response to pioglitazone treatment in patients with predi-
abetes or type 2 diabetes mellitus and nonalcoholic steatohepatitis.
Diabetes 64:A337 (Abstract)
46. DeFronzo RA, Tripathy D, Schwenke DC et al (2011) Pioglitazone
for diabetes prevention in impaired glucose tolerance. N Engl JMed
364:1104–1115
47. Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S (2013) Cohort
study of non-alcoholic fatty liver disease, NAFLD fibrosis score,
and the risk of incident diabetes in a Korean population. Am J
Gastroenterol 108:1861–1868
48. Aithal GP, Thomas JA, Kaye PVet al (2008) Randomized, placebo-
controlled trial of pioglitazone in nondiabetic subjects with nonal-
coholic steatohepatitis. Gastroenterology 135:1176–1184
49. Sanyal AJ, Chalasani N, Kowdley KV et al (2010) Pioglitazone,
vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J
Med 362:1675–1685
50. Berria R, Gastaldelli A, Lucidi S et al (2006) Reduction in hemat-
ocrit level after pioglitazone treatment is correlated with decreased
plasma free testosterone level, not hemodilution, in women with
polycystic ovary syndrome. Clin Pharmacol Ther 80:105–114
51. Balas B, Belfort R, Harrison S et al (2007) Pioglitazone treatment
increases whole body fat but not total body water in patients with
non-alcoholic steatohepatitis. J Hepatol 47:565–570
52. VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr
JJ, Lima JA (2015) Association of nonalcoholic fatty liver disease
with subclinical myocardial remodeling and dysfunction: a
population-based study. Hepatology 62:773–783
53. Yau H, Rivera K, Lomonaco R, Cusi K (2013) The future of
thiazolidinedione therapy in the management of type 2 diabetes
mellitus. Curr Diab Rep 13:329–341
54. Lewis JD, Habel LA, Quesenberry CP et al (2015) Pioglitazone use
and risk of bladder cancer and other common cancers in persons
with diabetes. JAMA 314:265–277
55. Portillo-Sanchez P, Cusi K (2016) Treatment of nonalcoholic fatty
liver disease (NAFLD) in patients with type 2 diabetes mellitus.
Clin Diab Endocrinol (in press)
56. Armstrong MJ, Houlihan DD, Rowe IA et al (2013) Safety and
efficacy of liraglutide in patients with type 2 diabetes with elevated
liver enzymes: individual patient data meta-analysis of the LEAD
programme. Aliment Pharmacol Ther 37:234–242
57. Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety
and efficacy in patients with non-alcoholic steatohepatitis (LEAN):
a multicentre, double-blind, randomised, placebo-controlled phase
2 study. Lancet 387:679–690
58. Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM,
Gathercole LL (2016) Glucagon-like peptide 1 decreases
lipotoxicity in non-alcoholic steatophepatitis. J Hepatol 64:399–
408
59. Portillo P, Yavuz S, Bril F, Cusi K (2014) Role of insulin resistance
and diabetes in the pathogenesis and treatment of nonalcoholic fatty
liver disease. Curr Hepatol Rep 13:159–170
60. Gupta NA, Mells J, Dunham RM et al (2010) Glucagon-like pep-
tide-1 receptor is present on human hepatocytes and has a direct role
in decreasing hepatic steatosis in vitro by modulating elements of
the insulin signaling pathway. Hepatology 51:1584–1592
61. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De
Minicis S, Candelaresi C (2011) Glucagon-like peptide-1 receptor
activation stimulates hepatic lipid oxidation and restores hepatic
signalling alteration induced by a high-fat diet in nonalcoholic
steatohepatitis. Liver Int 31:1285–1297
62. Iwasaki T, Yoneda M, Inamori M et al (2011) Sitagliptin as a novel
treatment agent for non-alcoholic fatty liver disease patients with
type 2 diabetes mellitus. Hepatogastroenterology 58:2103–2105
63. Fukuhara T, Hyogo H, Ochi H et al (2014) Efficacy and safety of
sitagliptin for the treatment of nonalcoholic fatty liver disease with
type 2 diabetes mellitus. Hepatogastroenterology 61:323–328
64. Macauley M, Hollingsworth KG, Smith FE et al (2015) Effect of
vildagliptin on hepatic steatosis. J Clin Endocrinol Metab 100:
1578–1585
65. Mudaliar S, Polidori D, Zambrowicz B, Henry RR (2015) Sodium-
glucose cotransporter inhibitors: effects on renal and intestinal glu-
cose transport: from bench to bedside. Diabetes Care 38:2344–2353
66. Hayashizaki-Someya Y, Kurosaki E, Takasu T et al (2015)
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect
on hepatic steatosis and fibrosis induced by choline-deficient L-
amino acid-defined diet in rats. Eur J Pharmacol 754:19–24
67. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J et al (2013)
Efficacy and safety of canagliflozin compared with placebo and
sitagliptin in patients with type 2 diabetes on background metfor-
min monotherapy: a randomised trial. Diabetologia 56:2582–2592
68. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of
dapagliflozin in patients with type 2 diabetes who have inadequate
glycaemic control with metformin: a randomised, double-blind,
placebo-controlled trial. Lancet 375:2223–2233
69. Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S (2016) Effect
of canagliflozin on liver function tests in patients with type 2 dia-
betes. Diabetes Metab 42:25–32
70. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA (2009)
A pilot study using simvastatin in the treatment of nonalcoholic
steatohepatitis: a randomized placebo-controlled trial. J Clin
Gastroenterol 43:990–994
71. Loomba R, Sirlin CB, Ang B et al (2015) Ezetimibe for the treat-
ment of nonalcoholic steatohepatitis: assessment by novel magnetic
resonance imaging and magnetic resonance elastography in a ran-
domized trial (MOZART trial). Hepatology 61:1239–1250
72. Fabbrini E, Mohammed BS, Korenblat KM et al (2010) Effect of
fenofibrate and niacin on intrahepatic triglyceride content, very
low-density lipoprotein kinetics, and insulin action in obese sub-
jects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab
95:2727–2735
73. Dasarathy S, Dasarathy J, Khiyami A et al (2015) Double-blind
randomized placebo-controlled clinical trial of omega 3 fatty acids
for the treatment of diabetic patients with nonalcoholic
steatohepatitis. J Clin Gastroenterol 49:137–144
74. Le TA, Chen J, Changchien C et al (2012) Effect of colesevelam on
liver fat quantified by magnetic resonance in nonalcoholic
steatohepatitis: a randomized controlled trial. Hepatology 56:922–
932
Diabetologia (2016) 59:1112–1120 1119
75. Klein EA, Thompson IM, Tangen CM et al (2011) Vitamin E and
the risk of prostate cancer: updated results of the Selenium and
Vitamin E Cancer Prevention Trial (SELECT). JAMA 306:1549–
1556
76. Van Wagner LB, Koppe SW, Brunt EM et al (2011) Pentoxifylline
for the treatment of non-alcoholic steatohepatitis: a randomized
controlled trial. Ann Hepatol 10:277–286
77. Zein CO, Yerian LM,Gogate P et al (2011) Pentoxifylline improves
nonalcoholic steatohepatitis: a randomized placebo-controlled trial.
Hepatology 54:1610–1619
78. Stefan N, Ramsauer M, Jordan P et al (2014) Inhibition of 11β-
HSD1 with RO5093151 for non-alcoholic fatty liver disease: a
multicentre, randomised, double-blind, placebo-controlled trial.
Lancet Diabetes Endocrinol 2:406–416
79. Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M,
Gilat T (2014) The fatty acid-bile acid conjugate aramchol reduces
liver fat content in patients with nonalcoholic fatty liver disease.
Clin Gastroenterol Hepatol 12:2085–2091
80. Cariou B, Staels B (2014) GFT505 for the treatment of nonalcohol-
ic steatohepatitis and type 2 diabetes. Expert Opin Investig Drugs
23:1441–1448
81. Staels B, Rubenstrunk A, Noel B et al (2013) Hepatoprotective
effects of the dual peroxisome proliferator-activated receptor
alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty
liver disease/nonalcoholic steatohepatitis. Hepatology 58:1941–
1952
82. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A et al (2008)
Alternative M2 activation of Kupffer cells by PPARδ ameliorates
obesity-induced insulin resistance. Cell Metab 7:496–507
83. Cariou B, Hanf R, Lambert-Porcheron S et al (2013) Dual peroxi-
some proliferator-activated receptor α/δ agonist GFT505 improves
hepatic and peripheral insulin sensitivity in abdominally obese sub-
jects. Diabetes Care 36:2923–2930
84. Belfort R, Berria R, Cornell J, Cusi K (2010) Fenofibrate reduces
systemic inflammation markers independent of its effects on lipid
and glucose metabolism in patients with the metabolic syndrome. J
Clin Endocrinol Metab 95:829–836
85. Ratziu V, Harrison S, Francque SM et al (2016) Elafibranor, an
agonist of the peroxisome proliferator-activated receptor-α and -δ,
induces resolution of non-alcoholic steatohepatitis without fibrosis
worsening. Gastroenterology. doi:10.1053/j.gastro.2016.01.038
86. Lefebvre E, Hashiguchi T, Jenkins H et al (2013) Anti-fibrotic and
anti-inflammatory activity of the dual CCR2 and CCR5 antagonist
cenicriviroc in a mouse model of NASH. Hepatology 58(S1):
221A–222A (Abstract)
87. Krenkel O, Püngel T, Mossanen JC et al (2015) Dual CCR2 and
CCR5 antagonist cenicriviroc leads to potent and significant reduc-
tion in proinflammatory CCR2+ monocyte infiltration in experi-
mental acute liver injury. Hepatology 62(S1):1065 (Abstract no.
1756)
88. Friedman S, Sanyal A, Goodman Z et al (2016) Efficacy and safety
study of cenicriviroc for the treatment of non-alcoholic
steatohepatitis in adult subjects with liver fibrosis: CENTAUR
Phase 2b study design. Contemp Clin Trials 47:356–365
89. Traber PG, Zomer E (2013) Therapy of experimental NASH and
fibrosis with galectin inhibitors. Plos One 8:e83481
90. Fisher FM, Chui PC, Nasser IA et al (2014) Fibroblast growth
factor 21 limits lipotoxicity by promoting hepatic fatty acid activa-
tion in mice on methionine and choline-deficient diets.
Gastroenterology 147:1073–1083
91. Jiang C, Xie C, Li F et al (2015) Intestinal farnesoid X receptor
signaling promotes nonalcoholic fatty liver disease. J Clin Invest
125:386–402
92. Neuschwander-Tetri BA, Loomba R, Sanyal AJ et al (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cir-
rhotic, non-alcoholic steatohepatitis (FLINT): a multicentre,
randomised, placebo-controlled trial. Lancet 385:956–965
93. Mudaliar S, Henry RR, Sanyal AJ et al (2013) Efficacy and safety
of the farnesoid X receptor agonist obeticholic acid in patients with
type 2 diabetes and nonalcoholic fatty liver disease.
Gastroenterology 145:574–582
94. Neuschwander-Tetri BA (2010) Hepatic lipotoxicity and the path-
ogenesis of nonalcoholic steatohepatitis: the central role of
nontriglyceride fatty acid metabolites. Hepatology 52:774–788
95. Dufour J-F (2016) Time to abandon NASH? Hepatology 63:9–10
1120 Diabetologia (2016) 59:1112–1120
